Mycobacterium tuberculosis

Copyright © 2015 Vishwanath Venketaraman et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Mycobacterium tuberculosis (M. tuberculosis), the causative agent for tuberculosis (TB), is responsible for 1.5 million deaths and 9 million new cases of TB in 2013 [1]. Lack of highly specific and sensitive diagnostic tests, restricted vaccine efficacy, emergence of multidrug and extensively drug-resistant strains of M. tuberculosis, and HIV coinfection are the most important factors that result in poor global TB control [1]. It is estimated that, among individuals who are infected with M. tuberculosis, around 85–90% are able to control the infection but are unable to completely eradicate the bacillus from their bodies resulting in a latent tuberculosis infection (LTBI) [2]. LTBI is defined by the presence of M. tuberculosis-specific immune response with the absence of radiological evidence of clinical disease and clinical signs or symptoms. Approximately one-third of the world's population has LTBI and, among the latently infected population, 5–10% will develop active TB due to reactivation and resuscitation of dormant bacilli [1]. This risk is further increased in immune-compromised individuals and people at the extremes of age. Latently infected individuals are the largest reservoir of potential future source of active TB [2]. In order to reduce the global incidence of TB cases, we urgently need an improved vaccine against M. tuberculosis infection. Mycobacterium bovis Bacillus Calmette-Guérin (M. bovis BCG), currently the only available vaccine against TB, induces variable protection in adults [3]. Immune correlates of protection are lacking, and analyses on cytokine-producing T-cell subsets in protected versus nonprotected cohorts have yielded inconsistent results [3]. This special issue encompasses findings from clinical and translational studies that will further enhance our understanding of the viru-lence mechanisms of M. tuberculosis, impaired host immune responses in individuals with active TB, pathogenesis of the disease, and strategies to enhance the innate and adaptive immune responses against M. tuberculosis infection. Within this special issue are studies that explore the use of BCG vaccines that have been modified in various ways to improve their efficacy. One study uses BCG-Pasteur and BCG-China with DNA vaccine priming and boosting. The vaccine contains coding regions for antigens present within the RD-14 region absent in BCG-Pasteur. In a separate study, BCG was made as a recombinant strain with overexpression of a …